Invited by Ontario's Ministry of Economic Development and Innovation and the Canadian Trade Commissioner Service, these meeting provided an opportunity for potential collaboration ...
CardioComm Solutions, Inc. (CardioComm Solutions) (TSX VENTURE: EKG)
was identified as a company of interest to participate in a one day
exchange (March 7, 2012) of information and ideas with a visiting
Japanese medical technology delegation sponsored by the Ontario's
Ministry of Economic Development and Innovation, in partnership with
the Canadian Trade Commissioner Service. The objectives of the mission
were to promote partnership in innovation, R&D, trade and investment
in the area of medical imaging between Canada and Japan.
The one-on-one meetings between CardioComm Solutions and the visiting
Japanese companies explored areas of collaboration which could lead to
new commercialization opportunities for CardioComm Solutions'
bio-monitoring technologies. Given the confidential nature of the
meetings and to respect the wishes of the delegation and the Canadian
Trade Commissioner Service, the participating organizations from the
Japanese delegation will not be disclosed at this date.
CardioComm Solutions is a medical software engineering company
specializing in the management of electrocardiograms ("EKGs"), one of
the most common diagnostic tests performed. Over the past three years
the company has successfully launched solutions that enable the
receipt, review and interpretation of EKGs through the use of newer
medical devices and communication portals over internet and cellular
based technologies. Their EKG management solutions can now service
both medical and consumer markets internationally. "Our Global EKG
Management System (GEMS) is comprised of two technologies. The first
enables the capture and importation of EKG recordings from FDA cleared
devices such as the HeartCheck PEN, Mobile Cardiac Telemetry Devices
("MCT"), 12 lead EKG machines and cardiac event loop recorders
("ELRS"). Our second proprietary technology is an EKG "viewer" that
forms the core of our family of products allowing the EKG wave form to
be acquired, reviewed, interpreted and saved, thereby enabling medical
professionals to make diagnoses for cardiac arrhythmias. Our EKG SDK
viewer is a technology of specific interest to our larger clients as
it can be integrated to their own proprietary workflow systems without
GEMS," said Etienne Grima, CEO of CardioComm Solutions.
"Discussions with the visiting delegates highlighted the importance of
having access to ready-to-market and proven medical solutions. The
Japanese market is active in searching out technologies such as ours
to service their growing In-Hospital, Point of Care and Home
Monitoring needs. With over 200 million citizens, the consumer market
importance also cannot be understated. Follow up discussions are
planned as well as the potential for a CardioComm Solutions visit to
Japan in 2012," added Grima.
"We were very pleased to have been asked to attend the closed door
meetings and to learn more about Japanese advanced technologies. The
meetings also allowed us to share our plans for leveraging our history
of performance in the health care market as we take first steps
towards integrating with new consumer EKG and other bio-sign
monitoring devices under the GEMSTM 4.0 software platform. This event
presented an excellent opportunity for access into the Japanese
market, a medical device market worth approximately $32 billion," said
Simi Grosman, member of the board of directors for CardioComm
About CardioComm Solutions
CardioComm Solution's patented and proprietary technology is used in
products for recording, viewing, analyzing and storing
electrocardiograms for diagnosis and management of cardiac patients.
CardioComm Solutions also is cleared by the FDA for the sales of a
consumer based HeartCheck PEN handheld EKG device and home version of
its proprietary GEMS Home software. Products are sold worldwide
through a combination of an external distribution network and a North
American-based sales team. The company has earned the ISO 13485
certification, is HPB approved, HIPAA compliant, and has received FDA
market clearance for its software devices. CardioComm Solutions, Inc.
is headquartered in Toronto, Canada, with offices in Victoria, B.C.
This release may contain certain forward-looking statements with
respect to the financial condition, results of operations and business
of CardioComm Solutions and certain of the plans and objectives of
CardioComm Solutions with respect to these items. By their nature,
forward-looking statements involve risk and uncertainty because they
relate to events and depend on circumstances that will occur in the
future and there are many factors that could cause actual results and
developments to differ materially from those expressed or implied by
these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.